ArticleEuropean journal of medical research2025
Development of a PPP1R14B-associated immune prognostic model for hepatocellular carcinoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study sought to comprehensively examine PPP1R14B's function and its immune-related correlations in hepatocellular carcinoma (HCC).
methodsRNA-seq and clinical information for HCC were procured from TCGA database. The links between PPP1R14B level and immune modulators plus immune cell populations were examined through Spearman correlation assessment. The immune landscape was assessed utilizing CIBERSORT and ESTIMATE algorithms. Gene set variation examination helped explore immune cell populations and their activities. The construction of prognostic models involved univariate and multivariate Cox regression investigations. Immunotherapy response and drug sensitivity were evaluated based on tumor immune dysfunction and exclusion (TIDE) and genomics of drug sensitivity in cancer (GDSC), respectively.
resultsPPP1R14B levels were substantially elevated in HCC specimens versus normal tissues, and elevated expression independently linked to diminished survival rates. PPP1R14B levels exhibited notable associations with various immune cells, including memory B lymphocytes, M1/M2 macrophage populations, CD8-positive T lymphocytes, and T follicular helper cells. The analysis revealed distinct variations in immune scores and multiple immune cell enrichment patterns between elevated and reduced PPP1R14B expression categories, suggesting immune status connections. Elevated PPP1R14B cohorts demonstrated increased TIDE scores, alongside decreased IC50 measurements for specific drugs, including temsirolimus, sorafenib, rapamycin, dasatinib, and cytarabine, pointing to treatment response relationships. The study constructed a PPP1R14B-linked immune prediction model, demonstrating acceptable prognostic capability for HCC patients. The incorporation of pathological grade and pathological T stage parameters alongside risk scores in a nomogram enhanced the predictive accuracy.
conclusionsThis investigation thoroughly uncovered the significance of PPP1R14B in HCC, and established a PPP1R14B-linked immune prognostic signature. The findings facilitate the classification of HCC patients into distinct cohorts for developing individualized therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.